First Quarter 2024

Earnings Highlights

$14.9B
Revenue
-19% Op[1] Decline
+11% Op Growth excl. COVID-19 products

$0.55
Rep. Dil. EPS[2]
-44% Decline

$0.82
Adj. Dil. EPS[2,3]
-32% Op Decline

$2.4B
Cash Dividends Returned to Shareholders
$0.42 Per Share of Common Stock

$2.5B
Rep. R&D Expenses

Revenue
$58.5B–$61.5B
FY 2024 Guidance[4]
$2.15–$2.35 Adj. Dil. EPS[3]

"I am encouraged by a well-executed quarter, setting the tone for the year. Pfizer's commercial leadership is focused on data-driven opportunities across several key growth brands, both in the U.S. and internationally, and we intend to build on this positive momentum in the quarters ahead."

Albert Bourla
Chairman and Chief Executive Officer

First-Quarter 2024 Global Pharmaceutical Revenues

Primary Care	Specialty Care	Oncology
$7.2B Revenue	$3.8B Revenue	$3.5B Revenue
-37% Op Decline	+7% Op Growth	19% Op Growth

Key Revenue Growth Drivers

- Legacy Seagen® Portfolio
- Vyndaqel® Family[5]
- Eliquis®[6] (apixaban) tablets 5mg 2.5mg
- ABRYSVO™ Respiratory Syncytial Virus Vaccine
- Prevnar 20™[7] Family Pneumococcal 20-valent Conjugate Vaccine

Pipeline Spotlights[8]

Approved in EU — Prevnar 20®	Prevention of invasive disease, pneumonia and acute otitis media caused by *Streptococcus pneumoniae* in individuals from 6 weeks to less than 18 yrs.
Approved in EU — Velsipity™	Treatment of moderately to severely active ulcerative colitis in patients 16+ yrs who have had an inadequate response, lost response, or were intolerant to conventional therapy or a biological agent.
Approved in EU — Emblaveo®	Treatment of serious infections in adult patients caused by multidrug-resistant Gram-negative bacteria, including metallo-β-lactamase-producing bacteria.
Approved in U.S. — BEQVEZ™	Treatment of adults with moderate to severe hemophilia B who currently use factor IX prophylaxis therapy, or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes, and do not have neutralizing antibodies to adeno-associated virus serotype Rh74var capsi.
tivdak® tisotumab vedotin-tftv for injection 40 mg	EU regulatory filing for treatment of adults with recurrent or metastatic cervical cancer with disease progression on or after first-line therapy.
ADCETRIS® brentuximab vedotin	Positive Phase 3 overall survival results for treatment of patients with relapsed/refractory diffuse large B-cell lymphoma as combination therapy.
ABRYSVO™ Respiratory Syncytial Virus Vaccine	Positive Phase 3 top-line results in adults 60+ yrs following a second season from ongoing trial.
ABRYSVO™ Respiratory Syncytial Virus Vaccine	Positive Phase 3 top-line results in adults 18-59 yrs. at risk of developing severe respiratory syncytial virus-associated lower respiratory tract disease.

\>119M
Patients Impacted
YTD Q1 2024 with our medicines and vaccines[9]

2024 Key Priorities

Focused on executing with excellence against strategic goals to drive long-term growth

- **Achieve** world-class oncology leadership
- **Deliver** next wave of pipeline innovation
- **Maximize** performance of new products
- **Expand** margins by realigning cost base
- **Allocate** capital to enhance shareholder value

What's Next

Remains confident in ability to deliver operational growth and meaningful shareholder value long term.

- **Maintain** patient centricity
- **Scale** emerging tech platforms
- **Invest** in areas we can win
- **Foster** a culture of innovation
- **Reduce** approval development cycle times

ANTICIPATES Non-COVID 2024 operational revenue growth of 8% to10%[10]

investors.pfizer.com

Please reference Pfizer's Q1 2024 earnings release and SEC filings for additional information.

[1] Reference to operational variances pertain to period-over-period changes that exclude the impact of foreign exchange rates.
[2] First-quarter 2024 Reported and Adjusted diluted EPS were favorably impacted by $0.11 resulting from a $771 million final adjustment to the estimated non-cash Paxlovid revenue reversal of $3.5 billion recorded in the fourth quarter of 2023, reflecting 5.1 million of EUA-labeled treatment courses returned by the U.S. government through February 29, 2024 versus the estimated 6.5 million treatment courses that were expected to be returned as of December 31, 2023.
[3] Adjusted income and Adjusted diluted EPS are defined as U.S. GAAP net income attributable to Pfizer Inc. common shareholders and Reported diluted EPS attributable to Pfizer Inc. common shareholders before the impact of amortization of intangible assets, certain acquisition-related items, discontinued operations and certain significant items. See the reconciliations of certain GAAP Reported to Non-GAAP Adjusted information for the first quarter of 2024 and 2023 accompanying Pfizer's earnings release furnished with Pfizer's Current Report on Form 8-K dated May 1, 2024. Adjusted income and its components and Adjusted diluted EPS measures are not, and should not be viewed as, substitutes for U.S. GAAP net income and its components and diluted EPS. See the Non-GAAP Financial Measure: Adjusted Income section of Management's Discussion and Analysis of Financial Condition and Results of Operations in Pfizer's 2023 Annual Report on Form 10-K and the Non-GAAP Financial Measure: Adjusted Income section accompanying Pfizer's earnings release furnished with Pfizer's Current Report on Form 8-K dated May 1, 2024, for additional information.
[4] Total company guidance. Please see Pfizer's Q1 2024 earnings release for additional details and assumptions regarding Pfizer's 2024 financial guidance.
[5] Vyndaqel family includes global revenues from Vyndaqel, as well as revenues for Vyndamax in the U.S. and Vynmac in Japan.
[6] Primarily reflects alliance revenues and product revenues.
[7] Prevnar family includes revenues from Prevnar 20/Apexxnar (pediatric and adult) and Prevnar 13/Prevenar 13 (pediatric and adult).
[8] Pipeline updates as of May 1, 2024.
[9] The Patients Impacted metric is calculated from Pfizer and third-party datasets. Figures may be limited given the coverage provided by external sources (e.g., calendar duration, geographic and product coverage) and are subject to change. Numbers are estimates and in some cases use global volume, daily dosage and number of treatment days to facilitate calculations. Methodologies to calculate estimates may vary by product type given the nature of the product and available data. Patients taking multiple Pfizer products may be counted as multiple patients towards total. Numbers do not include comprehensive estimated patient counts from Ex-U.S. Access & Affordability programs. Historical estimates may periodically be subject to revision due to restatements in the underlying data source.
[10] Please see Pfizer's press release issued on December 13, 2023, as well as Pfizer's Q1 2024 earnings release for additional details and assumptions regarding Pfizer's 2024 financial guidance.

This document includes forward-looking statements about, among other things, Pfizer's anticipated operating and financial performance, including financial guidance and projections, product pipeline, in-line products and product candidates, product launches, revenue contributions, business plans, strategy, goals and prospects, growth potential, business development activities, manufacturing and product supply, capital allocation objectives, dividends and share repurchases that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Please refer to Pfizer's Annual Report on Form 10-K for the year ended December 31, 2023, and its subsequent reports on Form 10-Q, including the sections thereof captioned "Risk Factors" and "Forward-Looking Information and Factors That May Affect Future Results," as well as Pfizer's subsequent reports on Form 8-K for a description of the substantial risks and uncertainties related to the forward-looking statements included in this document. These reports are available on Pfizer's website at www.pfizer.com and on the U.S. Securities and Exchange Commission's website at www.sec.gov. The forward-looking statements in this document speak only as of the original date of this document, and we undertake no obligation to update or revise any of these statement.